CN115057850A - 一种芦荟大黄素衍生物及其制备方法和应用 - Google Patents
一种芦荟大黄素衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115057850A CN115057850A CN202210844678.2A CN202210844678A CN115057850A CN 115057850 A CN115057850 A CN 115057850A CN 202210844678 A CN202210844678 A CN 202210844678A CN 115057850 A CN115057850 A CN 115057850A
- Authority
- CN
- China
- Prior art keywords
- aloe
- compound
- formula
- emodin
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical class C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000002207 metabolite Substances 0.000 claims abstract description 5
- 229940002612 prodrug Drugs 0.000 claims abstract description 5
- 239000000651 prodrug Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 12
- -1 hydroxy, cyano, amino Chemical group 0.000 claims description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 7
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000005251 aryl acyl group Chemical group 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 238000005893 bromination reaction Methods 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001893 coumarin derivatives Chemical class 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 description 52
- 150000001875 compounds Chemical class 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 29
- 239000002994 raw material Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 25
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 14
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 14
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 13
- 230000002194 synthesizing effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000003480 eluent Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 6
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 6
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 6-hydroxychromen-2-one Chemical compound O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 229960000956 coumarin Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 2
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- KPOVYMZGZNPRNA-UHFFFAOYSA-N 1-bromobut-1-yne Chemical compound CCC#CBr KPOVYMZGZNPRNA-UHFFFAOYSA-N 0.000 description 2
- VNFMAFVBJRIZEX-UHFFFAOYSA-N 3-(azidomethyl)-1,8-dihydroxyanthracene-9,10-dione Chemical compound O=C1C2=CC(CN=[N+]=[N-])=CC(O)=C2C(=O)C2=C1C=CC=C2O VNFMAFVBJRIZEX-UHFFFAOYSA-N 0.000 description 2
- HZLDTTNIJNQGEP-UHFFFAOYSA-N 3-(bromomethyl)-1,8-dihydroxyanthracene-9,10-dione Chemical compound O=C1C2=CC(CBr)=CC(O)=C2C(=O)C2=C1C=CC=C2O HZLDTTNIJNQGEP-UHFFFAOYSA-N 0.000 description 2
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- XLYOGWXIKVUXCL-UHFFFAOYSA-N 4-bromobut-1-yne Chemical compound BrCCC#C XLYOGWXIKVUXCL-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 2
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012650 click reaction Methods 0.000 description 2
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- ZXCUOCHXNYWBBG-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[2-methylpropyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CC(C)C)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CC(C)C)CC(C=C1)=CC=C1OC1=CC=CC=C1 ZXCUOCHXNYWBBG-ZQWQDMLBSA-N 0.000 description 1
- GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 1
- ORQHHLPTMSGMQT-UHFFFAOYSA-N 2-[4-(5-fluoropyridin-2-yl)piperazin-1-yl]-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide Chemical compound N1=CC(F)=CC=C1N1CCN(CC(=O)NC=2SC=3CCCCC=3N=2)CC1 ORQHHLPTMSGMQT-UHFFFAOYSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- WIRGBZBGYNIZIB-UHFFFAOYSA-N 4-hydroxy-6-methylchromen-2-one Chemical compound O1C(=O)C=C(O)C2=CC(C)=CC=C21 WIRGBZBGYNIZIB-UHFFFAOYSA-N 0.000 description 1
- MJBHLQMPKBMZSF-UHFFFAOYSA-N 4-hydroxy-7-methoxychromen-2-one Chemical compound OC1=CC(=O)OC2=CC(OC)=CC=C21 MJBHLQMPKBMZSF-UHFFFAOYSA-N 0.000 description 1
- MHZZDYJKWIQMFN-UHFFFAOYSA-N 4-hydroxy-7-methylchromen-2-one Chemical compound OC1=CC(=O)OC2=CC(C)=CC=C21 MHZZDYJKWIQMFN-UHFFFAOYSA-N 0.000 description 1
- HUMZENGQNOATEQ-UHFFFAOYSA-N 6-chloro-4-hydroxycoumarin Chemical compound C1=CC(Cl)=CC2=C1OC(=O)C=C2O HUMZENGQNOATEQ-UHFFFAOYSA-N 0.000 description 1
- JCOYNGQUPPGRNB-UHFFFAOYSA-N 6-fluoro-4-hydroxychromen-2-one Chemical compound C1=CC(F)=CC2=C1OC(=O)C=C2O JCOYNGQUPPGRNB-UHFFFAOYSA-N 0.000 description 1
- IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 1
- IJQYTHQDUDCJEQ-UHFFFAOYSA-N 7-hydroxy-2-oxochromene-3-carbonitrile Chemical compound C1=C(C#N)C(=O)OC2=CC(O)=CC=C21 IJQYTHQDUDCJEQ-UHFFFAOYSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- UFMQJYHLIUACCG-UHFFFAOYSA-N 8-nitroindolo[2,1-b]quinazoline-6,12-dione Chemical compound C1=CC=C2C(=O)N3C4=CC=C([N+](=O)[O-])C=C4C(=O)C3=NC2=C1 UFMQJYHLIUACCG-UHFFFAOYSA-N 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940126136 compound 5i Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000024305 myofibroblastoma Diseases 0.000 description 1
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了一种芦荟大黄素衍生物及其制备方法和应用,属于化学合成技术领域。本发明提供了一种新的芦荟大黄素衍生物,同时提供了一种芦荟大黄素衍生物的制备方法,制备得到的芦荟大黄素衍生物,或其立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药,在药用剂量下对多种癌细胞(如MCF‑7、HepG2、A549、SGC‑7901、HCT‑8等)的增殖均具有明显的抑制效果。
Description
技术领域
本发明属于化学合成技术领域,涉及一种芦荟大黄素衍生物及其制备方法和应用。
背景技术
芦荟大黄素是一类具有稠环芳香结构的多羟基蒽醌,具有下式结构,其较大的共轭芳香结构及多个羟基基团易于通过静电、氢键、π-π堆积、疏水作用等多种非共价键力与生物体内的核酸分子、细胞器中多种酶、蛋白质及其他生物活性位点发生作用,因而表现出多种生物医用价值,尤其是具有抗肿瘤的活性。
尽管芦荟大黄素具有抗肿瘤活性,但其自身活性强度以及生物利用度等问题限制了其进一步的应用于开发。因此对它的修饰与改造以及得到抗癌活性好而毒性较低的药物分子的研究变得十分重要并且普遍。
中国专利申请CN112778280A公开了一种蒽醌类天然产物改性衍生物,其采用分子杂交策略,将具有抗肿瘤活性的吲哚片段通过点击化学反应与芦荟大黄素进行分子杂交,具有式I的结构,该化合物在药用剂量下对多种癌细胞(如MCF-7、HepG2、AGS、SKOV3、Hela、A-549、MGC-803和Hacat等)的增殖均具有明显的抑制效果,并增强了芦荟大黄素母体分子的抗肿瘤活性。
中国专利申请CN109553579A公开了一种芦荟大黄素改性唑类化合物的制备方法及其应用,结构如通式IV所示,用于制备抗细菌和/或抗真菌药物中。
尽管现有技术中已经研究了芦荟大黄素衍生物具备一定的抗肿瘤活性,且可用于制备抗细菌和/或抗真菌药物,但仍然有必要探索更多新型的芦荟大黄素衍生物,同时芦荟大黄素衍生物在疾病中的治疗效果也还需要进一步探究。
发明内容
本发明的目的是提供一类结构新颖、具有抗癌活性的芦荟大黄素衍生物及其制备方法和应用。
为实现上述目的,本发明采用的技术方案如下:
一种芦荟大黄素衍生物,具有式I的结构:
其中:
R为下式结构的任意一种,
R1、R2、R3、R4各自独立选自以下取代基:H、羟基、氰基、氨基、卤素、硝基、烷基、氯代烷基、巯基、氧烷基、氨烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、杂环基、杂环基烷基、环烷基或环烷基烷基;
n=1-4;
R5、R6各自独立选自以下取代基:H、烷基、氯代烷基、烷氧基、烷氨基、芳基、芳基烷基、烷基酰基、芳基酰基、取代或未取代的磺酰基、烯丙基或炔丙基。
进一步地,R1、R2、R3、R4各自独立选自以下取代基:H、羟基、氰基、卤素、C1-6烷基、甲氧基、苯基或芳基烷基。
更进一步地,R1、R2、R3、R4各自独立选自以下取代基:H、羟基、氰基、卤素、甲基或甲氧基。
进一步地,R5、R6各自独立选自以下取代基:H、烷基、氯代烷基、氧烷基、氨烷基、芳基、芳基烷基、烷基酰基、芳基酰基、取代或未取代的磺酰基、烯丙基或炔丙基;优选地,R5、R6各自独立选自以下取代基:H、甲基、苄基、乙酰基、苯甲酰基和对甲苯磺酰基。
一种所述芦荟大黄素衍生物的制备方法,包括式Ⅱ和式Ⅲ在亚铜离子的催化作用下生成式Ⅳ的步骤,式Ⅱ为下式结构的任意一种,其中R’为-C≡CH或-CH2-C≡CH,
一种所述芦荟大黄素衍生物的制备方法,还包括以式Ⅳ为原料得到式Ⅴ的步骤,此时式Ⅴ中R5、R6不同时为H或同时不为H,
进一步地,式Ⅱ由香豆素衍生物a-d和溴代丙炔或溴代丁炔反应得到:
进一步地,式Ⅲ由式Ⅵ叠氮化钠反应得到:
进一步地,式Ⅵ由芦荟大黄素在四溴化碳/三苯基磷存在的条件下进行溴代反应得到,
本发明提供的式I化合物还可以通过以下制备方法得到,包括以式Ⅲ为原料得到式Ⅶ的步骤,还包括以式Ⅶ为原料得到式Ⅷ的步骤,
本领域技术人员可以理解的是,式Ⅶ中,当R为甲基时,可以由式Ⅲ和碘甲烷反应得到;当R为苄基时,可以由式Ⅲ和溴苄反应得到;当R为乙酰基时,可以由式Ⅲ和乙酰氯反应得到;当R为苯甲酰基时,可以由式Ⅲ和苯甲酰氯反应得到;当R为对甲基苯磺酰时,可以由式Ⅲ和对甲基苯磺酰氯反应得到。
本发明还提供了所述芦荟大黄素衍生物或所述制备方法得到的芦荟大黄素衍生物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
最后,本发明提供了一种所述的芦荟大黄素衍生物或所述的制备方法得到的芦荟大黄素衍生物或所述的芦荟大黄素衍生物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药在制备治疗癌症的药物中的应用。
所述癌症包括但不限于肺癌、结肠癌、前列腺癌、乳腺癌、肝癌、淋巴癌、甲状腺癌、多发性骨髓瘤、软组织肉瘤、卵巢癌、宫颈癌、输卵管癌、肾细胞癌、胃癌、胃肠道间质瘤、骨癌、基底细胞癌、腹膜癌、皮肤纤维瘤、胰腺癌、食管癌、胶质母细胞瘤、头颈癌、炎症性肌纤维母细胞瘤和间变性大细胞淋巴瘤中的一种或多种。
在具体的实施方式中,中间体2a-m的合成路线如下:
目标化合物5a-5m的合成路线如下:
中间体6a-6e、目标化合物7a-7e的合成路线如下:
其中,以香豆素1a~1m为起始原料,在碳酸钾、3-溴丙炔或4-溴-1-丁炔条件(条件a)下反应得中间体2a~2m。以芦荟大黄素为起始原料,在三苯基磷和四溴化碳的条件(条件b)下进行溴代反应,得中间体3。接着与叠氮化钠(条件c)反应得到叠氮化合物4。化合物4与中间体2a~2m在噻吩-2-甲酸亚铜催化条件下进行click反应(条件d)得目标化合物5a~5m。化合物4在碱性条件下与碘甲烷或溴苄反应(条件f),得中间体6a和6b;与乙酰氯和苯甲酰氯反应(条件e)得中间体6c和6d,与对甲基苯磺酰氯反应(条件g)得中间体6e。最后化合物6a~6e与中间体2d在噻吩-2-甲酸亚铜催化条件下进行click反应(条件h)得目标化合物7a~7e。
相对于现有技术,本发明具有以下有益效果:
(1)提供了一类新的芦荟大黄素衍生物,并且本发明提供的衍生物对多种癌细胞(如MCF-7、HepG2、A549、SGC-7901、HCT-8等)的增殖均具有明显的抑制效果;
(2)本发明芦荟大黄素改性母核和香豆素母核相结合,中间使用三氮唑进行连接,构建了“平面 柔性平面柔性平面”的交替结构,旨在探索这种结构对单纯的芦荟大黄素平面结构的增效作用,得到一批新结构的衍生物,在相同数量级浓度下对多种癌细胞具有生长抑制作用,可以持平甚至超过芦荟大黄素本身的效果,为芦荟大黄素改性的进一步应用提供了新的研究思路和参考。
具体实施方式
值得说明的是,本发明中使用的原料均为普通市售产品,对其来源不做具体限定。
实施例
1.中间体2a-m的合成
1.1 3-丙炔氧基香豆素2a的合成
将3-羟基香豆素1a(200mg,1.23mmol)溶于N,N-二甲基甲酰胺(5mL)中,依次加入碳酸钾(256mg,1.85mmol)和3-溴丙炔(293mg,2.46mmol)。加毕,60℃反应2h。TLC检测反应完全,停止反应,加水(60mL),乙酸乙酯(40mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-乙酸乙酯=6:1(V/V),得化合物2a,收率为89%。
1.2 4-丙炔氧基香豆素2b的合成
以4-羟基香豆素1b和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2b,收率为40%。
1.3 4-丙炔氧基-6-甲基香豆素2c的合成
以4-羟基-6-甲基香豆素1c和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2c,收率为44%。
1.4 4-丙炔氧基-6-氯香豆素2d的合成
以4-羟基-6-氯香豆素1d和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2d,收率为64%。
1.5 4-丙炔氧基-6-氟香豆素2e的合成
以4-羟基-6-氟香豆素1e和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2e,收率为55%。
1.6 4-丙炔氧基-7-甲基香豆素2f的合成
以4-羟基-7-甲基香豆素1f和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2f,收率为50%。
1.7 4-炔丙基-7-甲氧基香豆素2g的合成
以4-羟基-7-甲氧基香豆素1g和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2g,收率为43%。
1.8 6-丙炔氧基香豆素2h的合成
以6-羟基香豆素1h和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2h,收率为88%。
1.9 6-丙炔氧基-4-甲基香豆素2i的合成
以6-羟基-4甲基香豆素1i和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2i,收率为86%。
1.10 7-丙炔氧基香豆素2j的合成
以7-羟基香豆素1j和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2j,收率为81%。
1.11 7-丙炔氧基-4甲基香豆素2k的合成
以7-羟基-4甲基香豆素1k和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2k,收率为80%。
1.12 7-丙炔氧基-3氰基香豆素2l的合成
以7-羟基-3氰基香豆素1l和3-溴丙炔为原料,操作方法同化合物2a的合成,得化合物2l,收率为96%。
1.13 4-丁炔氧基香豆素2m的合成
以4-羟基香豆素1b和4-溴-1-丁炔为原料,操作方法同化合物2a的合成,得化合物2m,收率为35%。
2. 3-(溴甲基)-1,8-二羟基蒽-9,10-二酮(3)的合成
将三苯基磷(12.13g,46.25mmol)溶于四氢呋喃(400mL)中,分批将四溴化碳(15.34g,46.25mmol)加入反应液中,加毕,室温反应10min。将芦荟大黄素(5.0g,18.5mmol)加入反应液中,加毕,室温反应6h。TLC监测反应完全,停止反应,抽滤,滤饼用少量四氢呋喃洗涤,浓缩滤液,硅胶柱色谱纯化,洗脱剂:石油醚-二氯甲烷=1:1(V/V),得黄色固体5.66g,收率:92%。1H NMR(600MHz,DMSO-d6)δ11.92(s,1H),11.91(s,1H),7.82(dd,J=8.2Hz,8.0Hz,1H),7.78(d,J=1.7Hz,1H),7.72(dd,J=7.5Hz,1.1Hz,1H),7.47(d,J=1.7Hz,1H),7.40(dd,J=8.3Hz,1.1Hz,1H),4.82(s,2H)。
3. 3-(叠氮基甲基)-1,8-二羟基蒽-9,10-二酮(4)的合成
将化合物3(1.0g,3mmol)、叠氮化钠(215mg,3.3mmol)依次溶于乙腈(15mL)中,加热至60℃反应3h。TLC监测反应完全,停止反应,冷却至室温,加水(50mL),二氯甲烷(50mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-二氯甲烷=1:1(V/V),得黄色固体726mg,收率:82%。1H NMR(600MHz,DMSO-d6)δ11.92(s,1H),11.91(s,1H),7.82(dd,J=8.2Hz,7.5Hz,1H),7.71(dd,J=7.4Hz,1.1Hz,1H),7.68(d,J=1.6Hz,1H),7.39(dd,J=8.4Hz,1.1Hz,1H),7.35(d,J=1.6Hz,1H),4.68(s,2H)。
4.目标化合物5a-5m的合成
4.1化合物5a的合成
将化合物4(50mg,0.17mmol)溶于二氯甲烷(10mL)中,待溶解后加入化合物2a(38mg,0.19mmol)和噻吩-2-甲酸亚铜(3.8mg,0.02mmol),室温搅拌6h。TLC检测反应完全,停止反应,浓缩反应液,残留物硅胶柱色谱纯化,洗脱剂:二氯甲烷-甲醇=50:1(V/V),得黄色固体化合物5a,收率:57%。mp:252.3-254.1℃;1H NMR(600MHz,DMSO-d6)δ11.91-11.89(m,2H),8.49(s,1H),7.81(dd,J=8.4Hz,7.4Hz,1H),7.71(dd,J=7.4Hz,0.9Hz,1H),7.62-7.59(m,2H),7.57(s,1H),7.44(ddd,J=8.0Hz,7.4Hz,1.5Hz,1H),7.39(dd,J=8.4Hz,0.9Hz,1H),7.36(d,J=8.0Hz,1H),7.32(ddd,J=7.6Hz,7.4Hz,0.9Hz,1H),7.28(d,J=1.4Hz,1H),5.83(s,2H),5.26(s,2H);13C NMR(150MHz,DMSO-d6)δ191.5,181.2,161.4,161.3,156.5,149.2,145.6,142.5,142.0,137.5,133.9,133.3,128.6,127.0,125.8,124.8,124.5,122.9,119.6,119.4,118.3,116.0,115.8,115.7,115.1,62.1,52.1;HRMS m/z calcd for C27H18N3O7[M+H]+:496.1145;found:496.1147。
4.2化合物5b的合成
以化合物4和化合物2b为原料,操作方法同化合物5a的合成,得黄色固体5b,收率:46%。mp:272.5-273.8℃;1H NMR(600MHz,DMSO-d6)δ11.91(s,1H),11.90(s,1H),8.58(s,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.76(dd,J=7.9Hz,1.4Hz,1H),7.72(dd,J=7.5Hz,0.9Hz,1H),7.66(ddd,J=8.1Hz,7.4Hz,1.5Hz,1H),7.59(d,J=1.5Hz,1H),7.41(d,J=8.1Hz,1H),7.40(dd,J=8.4Hz,0.9Hz,1H),7.34(ddd,J=7.9Hz,7.4Hz,0.8Hz,1H),7.29(d,J=1.5Hz,1H),6.16(s,1H),5.85(s,2H),5.46(s,2H);13C NMR(150MHz,DMSO-d6)δ191.6,181.3,164.4,161.6,161.4,161.4,152.8,145.6,141.6,137.5,133.9,133.3,132.9,126.1,124.6,124.3,122.9,119.5,118.2,116.5,116.1,115.8,115.1,91.4,62.8,52.1;HRMS m/z calcd for C27H18N3O7[M+H]+:496.1145;found:496.1148.
4.3化合物5c的合成
以化合物4和化合物2c为原料,操作方法同化合物5a的合成,得黄色固体5c,收率:49%。mp:274.9-276.9℃;1H NMR(600MHz,DMSO-d6)δ11.91(s,1H),11.90(s,1H),8.57(s,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.71(dd,J=7.5Hz,0.8Hz,1H),7.58(d,J=1.5Hz,1H),7.51(d,J=2.0Hz,1H),7.46(dd,J=8.5Hz,2.0Hz,1H),7.40(dd,J=8.4Hz,0.8Hz,1H),7.32-7.27(m,2H),6.13(s,1H),5.85(s,2H),5.45(s,2H),2.34(s,3H);13C NMR(150MHz,DMSO-d6)δ191.5,181.3,164.4,161.7,161.4,161.4,151.0,145.6,141.5,137.5,133.9,133.7,133.6,133.3,126.1,124.6,122.9,122.3,119.4,118.1,116.3,116.0,115.8,114.8,91.3,62.7,52.1,20.3;HRMS m/z calcd for C28H20N3O7[M+H]+:510.1301;found:510.1299。
4.4化合物5d的合成
以化合物4和化合物2d为原料,操作方法同化合物5a的合成,得黄色固体5d,收率:82%。mp:286.3-288.1℃;1H NMR(600MHz,DMSO-d6)δ11.92-11.89(m,2H),8.59(s,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.73-7.67(m,3H),7.58(d,J=1.5Hz,1H),7.47(d,J=8.7Hz,1H),7.40(dd,J=8.4Hz,1.0Hz,1H),7.29(d,J=1.5Hz,1H),6.24(s,1H),5.85(s,2H),5.47(s,2H);13C NMR(150MHz,DMSO-d6)δ191.6,181.2,163.2,161.4,161.4,161.1,151.5,145.6,141.4,137.5,133.9,133.3,132.6,128.3,126.1,124.6,122.9,122.0,119.5,118.8,118.1,116.6,116.0,115.8,92.3,63.1,52.2;HRMS m/z calcd for C27H17ClN3O7[M+H]+:530.0755;found:530.0759。
4.5化合物5e的合成
以化合物4和化合物2e为原料,操作方法同化合物5a的合成,得黄色固体5e,收率:58%。mp:245.9-247.8℃;1H NMR(600MHz,DMSO-d6)δ11.94-11.80(m,2H),8.60(s,1H),7.79(dd,J=8.4Hz,7.4Hz,1H),7.68(dd,J=7.4Hz,0.5Hz,1H),7.55(d,J=1.3Hz,1H),7.51(dd,J=8.3Hz,2.8Hz,1H),7.48-7.44(m,2H),7.37(dd,J=8.4Hz,0.5Hz,1H),7.27(d,J=1.2Hz,1H),6.23(s,1H),5.84(s,2H),5.47(s,2H);13C NMR(150MHz,DMSO-d6)δ191.5,181.2,163.5,163.5,161.4,161.4(d,J=2.3Hz),158.1(d,J=241.3Hz),149.2,145.6,141.5,137.5,133.8,133.3,126.1,124.6,122.9,120.3(d,J=24.6Hz),119.4,118.8(d,J=8.5Hz),118.1,116.2(d,J=9.3Hz),116.0,115.8,108.5(d,J=25.5Hz),92.2,63.1,52.2;HRMS m/z calcd for C27H17FN3O7[M+H]+:514.1051;found:514.1053。
4.6化合物5f的合成
以化合物4和化合物2f为原料,操作方法同化合物5a的合成,得化合物黄色固体5f,收率:85%。mp:283.3-284.8℃;1H NMR(600MHz,DMSO-d6)δ11.94-11.90(m,2H),8.58(s,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.72(dd,J=7.5Hz,0.8Hz,1H),7.63(d,J=8.1Hz,1H),7.60(d,J=1.2Hz,1H),7.40(dd,J=8.4Hz,0.8Hz,1H),7.30(d,J=1.1Hz,1H),7.25-7.23(m,1H),7.16(dd,J=8.1Hz,0.7Hz,1H),6.10(s,1H),5.85(s,2H),5.44(s,2H),2.40(s,3H);13C NMR(150MHz,DMSO-d6)191.6,181.3,164.6 161.8,161.4,161.4,152.9,145.6,143.7,141.6,137.5,133.9,133.3,126.1,125.3,124.6,122.9,122.7,119.5,118.2,116.5,116.1,115.8,112.6,90.5,62.7,52.1,21.2;HRMS m/z calcd for C28H20N3O7[M+H]+:510.1301;found:510.1301。
4.7化合物5g的合成
以化合物4和化合物2g为原料,操作方法同化合物5a的合成,得黄色固体5g,收率:48%。mp:281.1-283.3℃;1H NMR(600MHz,DMSO-d6)δ11.92(s,1H),11.91(s,1H),8.56(s,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.72(dd,J=7.5Hz,1.0Hz,1H),7.64(d,J=8.9Hz,1H),7.60(d,J=1.5Hz,1H),7.40(dd,J=8.4Hz,1.0Hz,1H),7.29(d,J=1.5Hz,1H),6.99(d,J=2.4Hz,1H),6.91(dd,J=8.9Hz,2.4Hz,1H),6.00(s,1H),5.84(s,2H),5.43(s,2H),3.84(s,3H);13C NMR(150MHz,DMSO-d6)δ191.6,181.3,164.8,163.0,162.0,161.4,161.3,154.7,145.6,141.6,137.5,133.9,133.3,126.0,124.6,124.0,122.9,119.4,118.2,116.0,115.8,112.3,108.2,100.6,88.7,62.6,56.0,52.1;HRMS m/z calcd for C28H20N3O8[M+H]+:526.1250;found:526.1248。
4.8化合物5h的合成
以化合物4和化合物2h为原料,操作方法同化合物5a的合成,得黄色固体5h,收率:80%。mp:248.3-250.2℃;1H NMR(600MHz,DMSO-d6)δ11.92-11.89(m,2H),8.43(s,1H),7.99(d,J=9.6Hz,1H),7.82(dd,J=8.4Hz,7.5Hz,1H),7.71(dd,J=7.5Hz,1.0Hz,1H),7.58(d,J=1.5Hz,1H),7.42(d,J=3.0Hz,1H),7.40(dd,J=8.4Hz,1.0Hz,1H),7.35(d,J=9.1Hz,1H),7.28(dd,J=9.1Hz,3.0Hz,1H),7.24(d,J=1.5Hz,1H),6.49(d,J=9.6Hz,1H),5.81(s,2H),5.24(s,2H);13C NMR(150MHz,DMSO-d6)δ191.5,181.2,161.4,161.3,160.1,154.2,148.1,145.6,144.0,142.9,137.5,133.8,133.3,125.4,124.5,122.8,120.1,119.4,119.2,118.2,117.4,116.7,116.0,115.7,112.1,61.7,52.0;HRMS m/z calcd forC27H18N3O7[M+H]+:496.1145;found:496.1141。
4.9化合物5i的合成
以化合物4和化合物2i为原料,操作方法同化合物5a的合成,得黄色固体5i,收率:79%。mp:249.7-251.5℃;1H NMR(600MHz,DMSO-d6)δ11.91-11.89(m,2H),8.44(s,1H),7.81(dd,J=8.4Hz,7.5Hz,1H),7.70(dd,J=7.5Hz,1.0Hz,1H),7.56(d,J=1.6Hz,1H),7.39(dd,J=8.4Hz,1.0Hz,1H),7.36(d,J=2.8Hz,1H),7.34(d,J=9.0Hz,1H),7.30(dd,J=9.0Hz,2.8Hz,1H),7.24(d,J=1.6Hz,1H),6.38(d,J=1.2Hz,1H),5.81(s,2H),5.29(s,2H),2.41(d,J=1.1Hz,3H);13C NMR(150MHz,DMSO-d6)191.6,181.3,161.4,161.4,159.9,154.2,153.1,147.5,145.7,143.0,137.5,133.8,133.3,125.5,124.6,122.8,120.2,119.8,119.5,118.2,117.6,116.0,115.8,114.8,109.6,61.7,52.1,18.3;HRMS m/z calcdfor C28H20N3O7[M+H]+:510.1301;found:510.1305。
4.10化合物5j的合成
以化合物4和化合物2j为原料,操作方法同化合物5a的合成,得黄色固体5j,收率:94%。mp:265.2-266.9℃;1H NMR(600MHz,DMSO-d6)δ11.91-11.88(m,2H),8.46(s,1H),7.98(d,J=9.5Hz,1H),7.81(dd,J=8.4Hz,7.5Hz,1H),7.70(dd,J=7.5Hz,0.9Hz,1H),7.63(d,J=8.7Hz,1H),7.58(d,J=1.4Hz,1H),7.39(dd,J=8.4Hz,0.9Hz,1H),7.25(d,J=1.4Hz,1H),7.15(d,J=2.3Hz,1H),7.02(dd,J=8.7Hz,2.4Hz,1H),6.29(d,J=9.5Hz,1H),5.81(s,2H),5.31(s,2H);13C NMR(150MHz,DMSO-d6)δ191.5,181.2,161.4,161.3,161.0,160.2,155.3,145.6,144.3,142.5,137.5,133.8,133.2,129.5,125.6,124.5,122.8,119.4,118.2,116.0,115.7,112.9,112.7,112.6,101.6,61.6,52.1;HRMS m/z calcd forC27H18N3O7[M+H]+:496.1145;found:496.1146。
4.11化合物5k的合成
以化合物4和化合物2k为原料,操作方法同化合物5a的合成,得黄色固体5k,收率:88%。mp:233.7-235.6℃;1H NMR(600MHz,DMSO-d6)δ11.92-11.89(m,2H),8.47(s,1H),7.81(dd,J=8.4Hz,7.5Hz,1H),7.70(dd,J=7.5Hz,0.9Hz,1H),7.68(d,J=8.8Hz,1H),7.58(d,J=1.5Hz,1H),7.39(dd,J=8.4Hz,0.9Hz,1H),7.26(d,J=1.3Hz,1H),7.15(d,J=2.5Hz,1H),7.03(dd,J=8.8Hz,2.5Hz,1H),6.21(d,J=1.0Hz,1H),5.81(s,2H),5.31(s,2H),2.39(d,J=0.9Hz,3H);13C NMR(150MHz,DMSO-d6)δ191.6,181.3,161.4,161.4,161.0,160.2,154.7,153.5,145.6,142.5,137.5,133.9,133.3,126.6,125.7,124.6,122.9,119.5,118.2,116.0,115.8,113.4,112.7,111.4,101.6,61.6,52.1,18.2;HRMS m/z calcd forC28H20N3O7[M+H]+:510.1301;found:510.1303。
4.12化合物5l的合成
以化合物4和化合物2l为原料,操作方法同化合物5a的合成,得黄色固体5l,收率:54.2%。mp:258.4-260.2℃;1H NMR(600MHz,DMSO-d6)δ11.91-11.88(m,2H),8.85(s,1H),8.49(s,1H),7.80(dd,J=8.4Hz,7.4Hz,1H),7.73(d,J=8.8Hz,1H),7.69(d,J=7.4Hz,1H),7.55(d,J=1.3Hz,1H),7.39(d,J=8.4Hz,1H),7.29(d,J=2.3Hz,1H),7.25(d,J=1.1Hz,1H),7.13(dd,J=8.7Hz,2.3Hz,1H),5.82(s,2H),5.38(s,2H);13C NMR(150MHz,DMSO-d6)δ191.5,181.2,163.9,161.4,161.4,157.4,156.5,153.2,145.6,142.1,137.5,133.8,133.2,131.4,125.9,124.6,122.9,119.4,118.1,116.0,115.7,115.1,114.5,111.6,101.9,97.8,62.0,52.1;HRMS m/z calcd for C28H17N4O7[M+H]+:521.1097;found:521.1090。
4.13化合物5m的合成
以化合物4和化合物2m为原料,操作方法同化合物5a的合成,得黄色固体5m,收率:82%。mp:250.4-251.8℃;1H NMR(600MHz,DMSO-d6)δ11.90(s,1H),11.88(s,1H),8.22(s,1H),7.81(dd,J=8.4Hz,7.7Hz,1H),7.69-7.66(m,2H),7.56(ddd,J=8.4Hz,7.4Hz,1.6Hz,1H),7.48(d,J=1.6Hz,1H),7.39(dd,J=8.4Hz,0.9Hz,1H),7.31(dd,J=8.3Hz,0.6Hz,1H),7.25(ddd,J=7.8Hz,7.4Hz,0.9Hz,1H),7.21(d,J=1.6Hz,1H),5.94(s,1H),5.76(s,2H),4.47(t,J=6.2Hz,2H),3.25(t,J=6.2Hz,2H);13C NMR(150MHz,DMSO-d6)191.5,181.2,164.8,161.7,161.4,161.3,152.7,146.0,143.8,137.5,133.7,133.2,132.6,124.6,124.1,123.8,122.8,122.7,119.4,118.0,116.4,116.0,115.6,115.2,90.8,68.4,51.9,24.9;HRMS m/z calcd for C28H20N3O7[M+H]+:510.1301;found:510.1298。
5.中间体6a-6e的合成
5.1化合物6a的合成
依次将化合物4(50mg,0.17mmol)、碘甲烷(241mg,1.7mmol)和碳酸钾(235mg,1.7mmol)加到N,N-二甲基甲酰胺(3mL)中,加毕,60℃反应4h。TLC监测反应完全,停止反应,冷却至室温,加水(30mL),二氯甲烷(30mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:二氯甲烷-甲醇=50:1(V/V),得淡黄色固体48mg,收率:87%。mp:133.6-135.0℃。
5.2Bn-取代叠氮化物6b的合成
依次将化合物4(50mg,0.17mmol)、溴苄(145mg,0.85mmol)和碳酸钾(117mg,0.85mmol)加到N,N-二甲基甲酰胺(3mL)中,加毕,60℃反应4h。TLC监测反应完全,停止反应,冷却至室温,加水(50mL),乙酸乙酯(50mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-乙酸乙酯=5:1(V/V),得黄色固体54mg,收率:67%。mp:133.9-135.5℃。
5.3Ac-取代叠氮化物6c的合成
依次将化合物4(50mg,0.17mmol)、4-二甲氨基吡啶(4mg,0.03mmol)、乙酰氯(40mg,0.51mmol)及N,N-二异丙基乙胺(66mg,0.51mmol)加到二氯甲烷(3mL)中,加毕,室温反应4h。TLC监测反应完全,停止反应,冷却至室温,加水(30mL),二氯甲烷(30mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-乙酸乙酯=10:1(V/V),得淡黄色固体57mg,收率:89%。mp:161.2-162.8℃。
5.4Bz-取代叠氮化物6d的合成
依次将化合物4(50mg,0.17mmol)、4-二甲氨基吡啶(4mg,0.03mmol)、苯甲酰氯(72mg,0.51mmol)及N,N-二异丙基乙胺(66mg,0.51mmol)加到二氯甲烷(3mL)中,加毕,室温反应4h。TLC监测反应完全,停止反应,加水(30mL),二氯甲烷(30mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-乙酸乙酯=5:1(V/V),得淡黄色固体71mg,收率:83%。mp:175.6-176.8℃。
5.5Ts-取代叠氮化物6e的合成
将化合物4(50mg,0.17mmol)溶于丙酮(5mL),依次加入碳酸钾(70mg,0.51mmol)及对甲苯磺酰氯(82mg,0.43mmol),加毕,加热至60℃反应5h。TLC监测反应完全,停止反应,冷却至室温,加水(40mL),二氯甲烷(40mL×3)萃取,合并有机相,无水硫酸钠干燥,过滤,浓缩,硅胶柱色谱纯化,洗脱剂:石油醚-乙酸乙酯=5:1(V/V),得淡黄色固体85mg,收率:83%。mp:131.3-133.1℃。
6.目标化合物7a-7e的合成
6.1化合物7a的合成
将化合物6a(50mg,0.15mmol)、2d(42mg,0.18mmol)和噻吩-2-甲酸亚铜(6mg,0.03mmol)依次加到二氯甲烷(5mL)中,室温搅拌6h。TLC检测反应完全后,停止反应,浓缩反应液,残留物硅胶柱色谱纯化,洗脱剂:二氯甲烷-甲醇=50:1(V/V),得黄色固体7a69mg,收率:82%。mp:251.8-252.6℃;1H NMR(600MHz,DMSO-d6)δ8.59(s,1H),7.73(dd,J=8.3Hz,7.5Hz,1H),7.69(dd,J=8.8Hz,2.6Hz,1H),7.66-7.63(m,2H),7.57(d,J=0.7Hz,1H),7.52(d,J=8.3Hz,1H),7.49(d,J=0.7Hz,1H),7.45(d,J=8.8Hz,1H),6.24(s,1H),5.83(s,2H),5.46(s,2H),3.91(s,3H),3.90(s,3H);13C NMR(150MHz,DMSO-d6)183.0,180.9,163.2,161.1,159.0,158.8,151.5,142.3,141.3,134.5,134.4,134.0,132.6,128.3,126.0,123.3,123.1,122.0,119.1,118.8,118.2,118.1,117.0,116.6,92.3,63.1,56.5,56.4,52.5;HRMS m/z calcd for C29H21ClN3O7[M+H]+:558.1068;found:558.1070。
6.2化合物7b的合成
以化合物6b和化合物2d为原料,操作方法同化合物7a的合成,得黄色固体7b,收率:40%。mp:258.3-259.8℃;1H NMR(600MHz,DMSO-d6)δ8.57(s,1H),7.76(dd,J=8.3Hz,7.5Hz,1H),7.72-7.66(m,4H),7.65-7.60(m,5H),7.56(s,1H),7.46(d,J=8.7Hz,1H),7.43-7.38(m,4H),7.37-7.33(m,2H),6.26(s,1H),5.83(s,2H),5.46(s,2H),5.33(s,2H),5.32(s,2H);13C NMR(150MHz,DMSO-d6)182.9,180.9,163.2,161.1,158.0,157.7,151.5,142.2,141.3,136.9,136.6,134.6,134.4,134.2,132.6,128.4,128.3,127.8,127.7,127.0,126.9,126.0,123.8,123.6,122.0,120.6,119.7,118.7,118.7,117.5,116.6,92.3,70.3,70.1,63.1,52.4;HRMS m/z calcd for C41H29ClN3O7[M+H]+:710.1694;found:710.1690。
6.3化合物7c的合成
以化合物6c和化合物2d为原料,操作方法同化合物7a的合成,得黄色固体7c,收率:55%。mp:245.6-247.2℃;1H NMR(600MHz,DMSO-d6)δ8.61(s,1H),8.11(dd,J=7.6Hz,1H),7.98(s,1H),7.93(dd,J=7.9Hz,7.6Hz,1H),7.71(dd,J=8.7Hz,2.3Hz,1H),7.69(d,J=2.2Hz,1H),7.63(d,J=7.9Hz,1H),7.53(s,1H),7.48(d,J=8.7Hz,1H),6.25(s,1H),5.92(s,2H),5.47(s,2H),2.40-2.35(m,6H);13C NMR(150MHz,DMSO-d6)181.1,180.3,169.1,169.1,163.2,161.1,151.5,149.9,149.6,143.6,141.4,135.4,134.5,134.1,132.6,130.7,129.2,128.3,126.2,125.2,125.0,124.8,123.7,122.0,118.8,116.6,92.3,63.1,51.8,20.9,20.9;HRMS m/z calcd for C31H21ClN3O9[M+H]+:614.0966;found:614.0961。
6.4化合物7d的合成
以化合物6d和化合物2d为原料,操作方法同化合物7a的合成,得黄色固体7d,收率:83%。mp:231.1-232.6℃;1H NMR(600MHz,DMSO-d6)δ8.63(s,1H),8.16(dd,J=7.8Hz,1.1Hz,1H),8.04(d,J=1.6Hz,1H),7.98(dd,J=8.0Hz,7.8Hz,1H),7.94-7.91(m,4H),7.78(dd,J=8.0Hz,1.1Hz,1H),7.73(d,J=1.6Hz,1H),7.70(dd,J=8.8Hz,2.6Hz,1H),7.68(d,J=2.5Hz,1H),7.65-7.61(m,2H),7.46(d,J=8.8Hz,1H),7.43-7.37(m,4H),6.25(s,1H),5.95(s,2H),5.47(s,2H);13C NMR(150MHz,DMSO-d6)181.2,180.6,164.6,164.5,163.2,161.1,151.5,149.5,149.2,143.4,141.4,135.3,134.6,134.2,133.8,133.7,132.6,130.7,129.7,129.7,129.2,128.8,128.7,128.7,128.6,128.3,126.2,125.8,125.4,125.0,123.8,122.0,118.7,116.6,92.3,63.1,51.9;HRMS m/z calcd for C41H25ClN3O9[M+H]+:738.1279;found:738.1281。
6.5化合物7e的合成
以化合物6e和化合物2d为原料,操作方法同化合物7a的合成,得黄色固体7e,收率:95%。mp:195.6-197.1℃;1H NMR(600MHz,DMSO-d6)δ8.56(s,1H),8.10(dd,J=7.8Hz,1.1Hz,1H),8.03(d,J=1.6Hz,1H),7.89(dd,J=8.1Hz,7.8Hz,1H),7.80(d,J=8.3Hz,2H),7.75(d,J=8.3Hz,2H),7.69-7.65(m,2H),7.57(dd,J=8.1Hz,1.0Hz,1H),7.49(d,J=1.6Hz,1H),7.45(d,J=8.7Hz,1H),7.41(d,J=8.1Hz,2H),7.39(d,J=8.1Hz,2H),6.28(s,1H),5.92(s,2H),5.49(s,2H),2.37(s,3H),2.36(s,3H);13C NMR(150MHz,DMSO-d6)180.5,178.2,163.2,161.1,151.5 146.7,146.3,146.1,146.0,143.3,141.4,135.1,134.8,134.5,132.6,131.6,131.4,130.2,130.2,129.5,128.5,128.4,128.3,127.7,127.2,126.5,126.1,125.8,124.5,122.0,118.7,116.6,92.3,63.0,51.7,21.2,21.2;HRMS m/zcalcd for C41H29ClN3O11S2[M+H]+:838.0932;found:838.0931。
试验例 四氮噻唑蓝(MTT)法分析化合物对肿瘤细胞增殖的作用
分别取对数生长期细胞接种于96孔板培养,按100μL/well接种于96孔板内培养,待细胞贴壁后设组并按100μL/well分别加入经培养基稀释的不同浓度化合物,同时设置阳性药组、对照组(加入等体积的细胞悬液),各组均设3个复孔,置于5%CO2、37℃孵箱培养48h后,每孔按20μL/well加入MTT(5mg/mL),置于培养箱内孵育4h。吸弃各孔上清,加入DMSO,150μL/well,置于摇床上振荡10min后,使用酶标仪于490nm波长处检测每孔的吸光度(A)值,确定药物对肿瘤细胞生长的抑制率并计算细胞生长抑制率:细胞生长抑制率(%)=(1-给药组OD值/对照组OD值)×100%,具体数据见表1。
MCF-7:人乳腺癌细胞
HepG2:人肝癌细胞
A549:人非小细胞肺癌细胞
SGC-7901:人胃癌细胞
HCT-8:人回盲肠癌细胞
表1目标化合物5a-5m和7a-7e的体外抗肿瘤活性
最后应当说明的是,以上内容仅用以说明本发明的技术方案,而非对本发明保护范围的限制,本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换,均不脱离本发明技术方案的实质和范围。
Claims (10)
2.根据权利要求1所述的芦荟大黄素衍生物,其特征在于,所述R1、R2、R3、R4各自独立选自以下取代基:H、羟基、氰基、卤素、C1-6烷基、甲氧基、苯基或芳基烷基。
3.根据权利要求3所述的芦荟大黄素衍生物,其特征在于,所述R1、R2、R3、R4各自独立选自以下取代基:H、羟基、氰基、卤素、甲基或甲氧基。
4.根据权利要求1所述的芦荟大黄素衍生物,其特征在于,所述R5、R6各自独立选自以下取代基:H、烷基、氯代烷基、氧烷基、氨烷基、芳基、芳基烷基、烷基酰基、芳基酰基、取代或未取代的磺酰基、烯丙基或炔丙基;优选地,所述R5、R6各自独立选自以下取代基:H、甲基、苄基、乙酰基、苯甲酰基和对甲苯磺酰基。
9.权利要求1-4任一项所述的芦荟大黄素衍生物或权利要求5-8任一项所述的制备方法得到的芦荟大黄素衍生物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。
10.权利要求1-4任一项所述的芦荟大黄素衍生物或权利要求5-8任一项所述的制备方法得到的芦荟大黄素衍生物或权利要求9所述的芦荟大黄素衍生物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药在制备治疗癌症的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210844678.2A CN115057850B (zh) | 2022-07-18 | 2022-07-18 | 一种芦荟大黄素衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210844678.2A CN115057850B (zh) | 2022-07-18 | 2022-07-18 | 一种芦荟大黄素衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115057850A true CN115057850A (zh) | 2022-09-16 |
CN115057850B CN115057850B (zh) | 2023-11-10 |
Family
ID=83207197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210844678.2A Active CN115057850B (zh) | 2022-07-18 | 2022-07-18 | 一种芦荟大黄素衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115057850B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109553579A (zh) * | 2018-12-29 | 2019-04-02 | 西南大学 | 芦荟大黄素唑类化合物的制备方法及其应用 |
CN112778280A (zh) * | 2021-01-08 | 2021-05-11 | 中国医学科学院药用植物研究所 | 一种蒽醌类天然产物改性衍生物 |
-
2022
- 2022-07-18 CN CN202210844678.2A patent/CN115057850B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109553579A (zh) * | 2018-12-29 | 2019-04-02 | 西南大学 | 芦荟大黄素唑类化合物的制备方法及其应用 |
CN112778280A (zh) * | 2021-01-08 | 2021-05-11 | 中国医学科学院药用植物研究所 | 一种蒽醌类天然产物改性衍生物 |
Non-Patent Citations (2)
Title |
---|
曹丽华等: "芦荟大黄素唑类衍生物的合成及抗肿瘤作用研究", 《化学试剂》, vol. 41, no. 10, pages 1042 - 1045 * |
肖启桃等: "芦荟大黄素衍生物的合成和生物活性", 《中国化学会第四届有机化学学术会议》, pages 188 * |
Also Published As
Publication number | Publication date |
---|---|
CN115057850B (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1634881B1 (en) | Harmine derivatives, intermediates used in their preparation, preparation processes and use thereof | |
CN108117507A (zh) | 一种氮杂螺环己二烯酮的合成方法和用途 | |
CN106632271A (zh) | 具有抗肿瘤活性的厄洛替尼衍生物及其制备方法和应用 | |
CN104072493A (zh) | 一类含2-巯基苯并噻唑和三唑杂环的萘酰亚胺化合物,其制备方法及其应用 | |
WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
CN114195814A (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
CN110183503B (zh) | 磺酰氮杂螺癸二烯酮类化合物及其用途 | |
CN110642740B (zh) | 异斯特维醇酰胺衍生物及其制备方法 | |
CN115057850B (zh) | 一种芦荟大黄素衍生物及其制备方法和应用 | |
CN103435560B (zh) | 一类带柔性侧链的苊并[1,2-b]喹喔啉衍生物的合成及其应用 | |
CN113292629B (zh) | 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用 | |
CN107652338B (zh) | 糖偶联-1,2,3-三氮唑取代的多环芳烃衍生物在制备抗癌药物的用途 | |
CN113234117A (zh) | 常春藤皂苷元c-28位聚乙二醇修饰的衍生物及其制备方法 | |
CN111393416B (zh) | 含1-甲基吡啶-3-(4-氯苯基)吡唑单元的吡唑化合物的制备方法和应用 | |
WO1998023614A1 (fr) | Nouveaux derives du phenanthridinium | |
CN114621161B (zh) | 一种大黄酸-哌嗪-二硫代氨基甲酸酯杂化物及其制备方法和应用 | |
CN115304605B (zh) | 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用 | |
WO2024012568A1 (en) | A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof | |
CN109485641B (zh) | 一类酰胺键连接的尿嘧啶-咔唑类缀合物、合成及其应用 | |
CN115043784B (zh) | 一种联苯-1,2,3-三氮唑偶联物及其制备方法和应用 | |
CN111875605B (zh) | 含取代吡唑和β-咔啉单元的双酰胺类化合物的制备与应用 | |
WO2016206138A1 (zh) | 组蛋白去乙酰化酶抑制剂及其制备方法和应用 | |
CN107641141B (zh) | 糖偶联-1,2,3-三氮唑取代的多环芳烃衍生物及制备方法 | |
CN114933601A (zh) | 汉防己甲素衍生物及其制备方法和应用 | |
CN114437046A (zh) | 5-氟尿嘧啶拼接4-苯胺喹唑啉类化合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |